News for Alkermes plc (ALKS)

The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.

ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.

Total Revenue: Exceeded $1.5 billion in 2024, driven by proprietary commercial portfolio.EBITDA: More than $450 million for continuing operations in 2024.Cash

The following slide deck was published by Alkermes plc in conjunction with their 2024 Q4 earnings call.

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.

Shares of Alkermes PLC (ALKS) surged 3.97% in mid-day trading on Feb 12. The stock reached an intraday high of $33.23, up from its previous close of $31.96. T

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) delivered earnings and revenue surprises of 28.40% and 13.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Alkermes PLC (ALKS) announced its financial results for the year ending December 31, 2024, reporting total revenues of $1.56 billion, with a significant 18% inc

PR NewswireDUBLIN, Feb. 12, 2025 ”” Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Ye

Quarterly Revenue: $430 million, surpassing the estimated $379.74 million.Annual Revenue: $1.56 billion, exceeding the estimated $1.50755 billion, with proprie

**media[532850]**

Summary Alkermes PLC (ALKS), a global biopharmaceutical company specializing in neuroscience, announced on January 2, 2025, that its CEO, Richard Pops, will pre

PR NewswireDUBLIN, Jan. 2, 2025 DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard

212 firms in the S&P 1500 have not beaten even US treasuries over the last 10 years

Avadel Pharmaceuticals CFO buys $24,018 in stock

Alkermes director Cato Laurencin sells $85,708 in stock

On December 5, 2024, Craig Hopkinson, Executive Vice President of Research and Development and Chief Medical Officer at Alkermes Research and Development, a bra

Alkermes' chief medical officer sells $290,461 in stock